Status:

COMPLETED

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled 14-week Study of DS-5565 in Chinese Patients With Diabetic Peripheral Neuropathic Pain

Lead Sponsor:

Daiichi Sankyo Co., Ltd.

Conditions:

Diabetic Peripheral Neuropathic Pain

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

Investigate the efficacy and safety of mirogabalin in Chinese participants with diabetic peripheral neuropathic pain in comparison to placebo.

Detailed Description

The primary objective is to compare change from baseline in weekly Average Daily Pain Score (ADPS) at Week 14 in Chinese patients with Diabetic Peripheral Neuropathic Pain (DPNP) receiving mirogabalin...

Eligibility Criteria

Inclusion

  • Type 1 or type 2 diabetes mellitus at screening
  • Painful distal symmetric polyneuropathy, diagnosed at least 6 months prior to screening (see Procedures manual for the Diagnosis of Diabetic Peripheral Neuropathy and Neurological Examination for details)

Exclusion

  • HbA1c (National Glycohemoglobin Standardization Program) \> 10.0% at screening
  • Uncontrolled blood glucose within 1 month prior to screening, at screening or randomization
  • Other severe pain at screening or randomization, unrelated to DPN, that may confound the assessment of DPNP
  • Neurologic disorders at screening or randomization, unrelated to DPN, that may confound the assessment of DPNP
  • Major psychiatric disorders at screening or randomization
  • Creatinine clearance (using the Cockcroft-Gault equation) \< 60 mL/min at screening

Key Trial Info

Start Date :

September 18 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 24 2022

Estimated Enrollment :

393 Patients enrolled

Trial Details

Trial ID

NCT04094662

Start Date

September 18 2019

End Date

January 24 2022

Last Update

October 24 2022

Active Locations (40)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 10 (40 locations)

1

Beijing Chaoyang Hospital, Capital Medical University

Beijing, China, 100020

2

Peking University First Hospital

Beijing, China, 100034

3

Beijing Friendship Hospital, Capital Medical University

Beijing, China, 100050

4

Xuanwu Hospital Capital Medical University

Beijing, China, 100053

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled 14-week Study of DS-5565 in Chinese Patients With Diabetic Peripheral Neuropathic Pain | DecenTrialz